These dying patients cannot get experimental drugs


By AGENCY

Autumn Fuernisen was diagnosed four years ago with a terminal brain disorder, juvenile-onset Huntington's disease. Patients with rare diseases often have difficulty qualifying for compassionate use programs for experimental therapies.- Londen Tabor/TNS

AT 15, Autumn Fuernisen is dying.

She was diagnosed at age 11 with a rare degenerative brain disorder that has no known cure or way to slow it down: juvenile-onset Huntington’s disease.

Save 30% for ads-free and full access now!

Monthly Plan

RM13.90/month
RM9.73 only

Billed as RM9.73 for the 1st month then RM13.90 thereafters.

Annual Plan

RM12.33/month
RM8.63/month

Billed as RM103.60 for the 1st year then RM148 thereafters.

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Health

Amazon drivers double up as first responders
Vitamin B12-enriched cream could help relieve dermatitis symptoms
The two types of brain aneurysms
The therapist's perspective: A ‘raw’ window into humanity
Losing their immunity after a measles infection
When autistic kids wander off
Protecting the night shift’s heart health
A guide to monitoring your child’s milestones
Age really is no barrier to exercise
When pneumonia turns deadly

Others Also Read